Frequently Asked Questions (FAQs)
What is the 7th Cell Therapy Analytical Development Summit?
The 7th Cell Therapy Analytical Development Summit (CTAD 2025) is your industry-leading meeting dedicated to advancing cell therapy analytics and supporting the successful progression of cell and gene therapies from discovery through to commercialization.
Taking place in December, this meeting looks to overcome analytical challenges across a range of modalities, including CAR-T therapies, autologous, allogeneic, and stem cell-based therapies.
With a keen focus on analytical methods, potency assay development, assay validation, method transfer, and process analytical technologies, we will provide you with cutting-edge strategies to improve chemistry, manufacturing and controls (CMC), ensure regulatory compliance, and drive robust product release decisions.
Now combined with the Cell Therapy Potency Assay Summit, this forum is your unrivalled opportunity to exchange knowledge, benchmark against peers and collaborate with the global cellular-based therapies community.
Who Should Attend this Cell Therapy Meeting?
This meeting has been crafted specifically for experts working across the cell therapy development and biotechnology analytics landscape.
Typical job titles and functions include:
- Analytical Development Scientists
- Heads of Quality Control and Quality Assurance
- Directors and Managers of Process Development and Cell Processing
- Regulatory Affairs Specialists, focused on regulatory compliance
- CMC, Clinical Development, and Supply Chain experts
- Assay Development and Validation Scientists, including cell-based assays, cellular assays and potency assays
- Professionals specializing in flow cytometry, immunophenotyping, cell viability, and cytotoxicity testing
- Specialists in cell therapy sterility testing and tech transfer
What Topics Will Be Covered in 2025?
Best practices for analytical method development, assay validation, and tech transfer
Advanced approaches to potency assay development and cell potency assays, for CAR-T cells, stem cells, and other cell-based therapies
Emerging tools for characterization, cell therapy sterility testing, and cytotoxicity assays
Applications of flow cytometry, immunophenotyping, and process analytical technologies in cell therapy development
Ensuring regulatory compliance and managing product release in the face of increased global scrutiny
Strategies for effective tech transfer, supply chain optimization, and long-term commercial success in cell-based therapeutics
What Are the Benefits of Attending this Year?
Attending in 2025 will offer you the chance to:
- Stay ahead of heightened regulatory compliance requirements and ensure alignment across the product development lifecycle
- Gain practical insights into overcoming barriers in potency assay development, cell therapy sterility testing, and analytical method transfer
- Network with leading experts in cell therapy analytics, clinical development, quality control, and biotechnology analytics
- Benchmark strategies alongside your peers, who are advancing both autologous and allogeneic cell therapies
Who Are the Key Speakers?
